Esperion Therapeutics, Inc.: directors' dealings · United States · SEC (Form 4)

About Esperion Therapeutics, Inc.

Esperion Therapeutics, Inc. is a U.S.-based biopharmaceutical company listed on the NASDAQ under the ticker ESPR, in the United States (United States). The company is focused on cardiovascular risk reduction, with a commercial and development strategy centered on oral bempedoic acid therapies for patients who are statin intolerant or insufficiently controlled on standard lipid-lowering treatment. From an equity research perspective, Esperion sits in the healthcare/pharma bucket as a specialty cardiometabolic platform with a focused commercial footprint and meaningful pipeline optionality. Esperion was founded in 2008 and rebuilt around a core scientific asset: bempedoic acid and the related intellectual property rights. Its corporate headquarters are in Ann Arbor, Michigan, giving the company a U.S. life-sciences base in a well-known biotech and academic corridor. Over time, Esperion evolved from a research-driven organization into a commercial-stage company, while still retaining a development mindset aimed at broadening its product set and geographic reach. The company’s marketed portfolio is anchored by NEXLETOL and NEXLIZET, oral therapies used to lower LDL cholesterol in appropriate patients, especially those unable to take statins at effective doses. That places Esperion in a competitive but clinically differentiated niche within the lipid-management market. Its competitive set includes large pharmaceutical franchises in statins, PCSK9 inhibitors and other LDL-lowering therapies, but Esperion’s differentiation lies in oral administration, a statin-intolerance proposition, and an increasingly established evidence base. Inclusion in clinical guidelines and payer access progress are important commercial supports. Geographically, the United States remains the main revenue engine, although Esperion also operates through collaborators and regulatory filings in international markets. In 2025, management highlighted strong momentum in U.S. prescription growth and product sales, including the milestone of surpassing one million prescriptions for its bempedoic-acid products. The company also discussed new marketing initiatives around statin intolerance and continued work on triple-combination oral products, as well as potential expansion into rare hepatic and renal disease opportunities. A major recent corporate development came in May 2026, when Esperion announced a definitive agreement to be acquired by ARCHIMED in a transaction valued at up to approximately $1.1 billion in total equity value, subject to commercial milestones. For investors tracking ESPR on the NASDAQ, that acquisition announcement is a key near-term strategic catalyst.